Industry Events

The American Society of Breast Surgeons (ASBrS) is pleased to offer Industry Events to the breast surgery community. Webinars are educational programs sponsored and funded by an outside organization, independently organized, and offered, and have been made possible through marketing support and advertising fees. Content is updated as programming details are received. See below for Upcoming Events and on-demand events for 20242023 & 2022.

Interested in Supporting an Activity or Webinar?

Please contact Marti Boyer at mboyer@breastsurgeons.org.


The following industry activities are supported by specific companies through marketing grants and advertising fees. They are not part of the official education program of the ASBrS, and most events are free to all members. By clicking the links posted below, please understand you may leave the ASBrS website and go to a website not operated by the Society.

Upcoming Events
There are no upcoming Industry Events. Members will be notified as registration opens for new events. In the meantime, use the tabs above to access previously recorded on-demand webinars.

 2024 Events on Demand

AstraZeneca

Dilon Technologies

Myriad Genetics

Natera


AstraZeneca

Best Practices for Utilizing Alternative Service Models for Genetic Counseling


Overview

As genetic counseling is recommended for an increasing number of patients with cancer, institutions are looking for new strategies to meet this growing demand. By developing efficient genetic counseling and testing service delivery models, more patients may be able to access crucial testing and targeted cancer treatment.

Hear directly from a genetic counselor at a community health system and a genetic counselor at an academic medical center as they share examples of alternative service delivery models, challenges they faced during the implementation of these workflows, and their impact on expanding access to genetic testing for appropriate patients.

Key Topics Include:

  • Strategies for accessible education in the pretest setting
  • Frameworks to integrate patients, physicians, nurse navigators, and testing coordinators into the genetic counseling process
  • Workflows to get genetic testing results quickly and streamline quality care

You can find this important roundtable discussion HERE.


Note: his webinar is supported by AstraZeneca through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 02/13/2024

Dilon Technologies

Evaluating New Technology in a Value Based Environment


Overview

As technology advances, surgeons need to develop tools to assess the value of new devices and initiatives in patient care. Surgeons will also need to understand the processes by which their institutions evaluate new technology for integration into the system.

Presented by:

  • Freya R. Schnabel, MD
    Professor, Department of Surgery at NYU Grossman School of Medicine
    Director of Breast Surgery
    NYU Langone Health
    New York, NY

Note: This webinar is supported by Dilon Technologies through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 04/02/2024

Myriad Genetics

Mastering Breast Cancer Genetics and Genomics Series: Part 2 — Risk Assessment and High-Risk Management


Overview

In Part 2 of our 3-Part series exploring the comprehensive genetics and genomics landscape in breast cancer, we'll dive into Risk Assessment and High-Risk Management. Come along as we explore strategies and tests to assess breast cancer risk and tools for implementing a high-risk breast program in your practice. Let's identify patients together who are at high risk for breast cancer so we can #BeatBreastCancer.


Note: This webinar is supported by Myriad Genetics through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 02/15/2024

Myriad Genetics

Mastering Breast Cancer Genetics and Genomics Series: Part 3 — Hot Topics in Breast Cancer Genetic Testing


Overview

Join Eric Manahan, MD, MBA, FACS, a leading expert in general and breast surgery, as he shares insights on trending topics in genetic testing for breast cancer. In this webinar, Dr. Manahan covers the importance and underutilization of genetic testing in breast cancer, disparities in genetic testing, unlocking the potential of tumor genomics, exciting research opportunities, and much more. Don't miss out — register today to secure your spot and gain valuable insights on how to elevate your approach to patient care.


Note: This webinar is supported by Myriad Genetics through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 05/22/2024

Natera

25th Annual Meeting Symposium
Actionable Insights Today: Staying one step ahead in breast cancer management with tumor informed MRD testing and comprehensive hereditary cancer testing


Overview

Join us as we take a dive deep into how tumor-informed molecular residual disease (MRD) testing is being integrated into clinical practice today as a valuable tool to help guide treatment decisions for patients with breast cancer. Our expert panel will review the various applications of tumor-informed ctDNA assessment in the neoadjuvant, adjuvant and surveillance settings.

Presenters:

  • Angel Rodriguez, MD
    Medical Oncologist, Breast Medical Director
    Natera
  • Erica Giblin, MD
    Surgeon, Breast Cancer Specialistr
    Ascension St. Vincent

Note: Symposia at the Society's 25th Annual Meeting were educational programs sponsored and funded by an outside organization, independently organized, and offered. This symposium was supported by Natera through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 4/10/2024

 2023 Events on Demand

AstraZeneca

Dilon Technologies

Exact Sciences

Mammotome

Merit Oncology

Myriad Genetics

Natera

Perimeter Medical Imaging AI


AstraZeneca

24th Annual Meeting Symposium
An MDT Perspective: Exploring the Integration and Impact of Germline BRCA Mutation Testing in Surgical Management of Early Breast Cancer


Overview

During this program, a multidisciplinary panel of experts will discuss the role and importance of surgeons in genetic testing in early breast cancer. Topics will include key characteristics and unmet needs of patients with germline BRCA mutations (gBRCAm), collaborating with the multidisciplinary team to integrate genetic testing in practice, genetic counseling considerations and how gBRCAm testing may inform clinical decisions. View prescribing information.

Program Objectives:

  • Discuss the need for individualized care plans for patients with gBRCAm breast cancer due to differences in underlying tumor biology vs non-gBRCAm patients
  • Discuss the surgical and treatment implications for patients with gBRCAm eBC
  • Explore the role and importance of surgeons within the BRCA testing pathway

Note: Symposia at the Society's 24th Annual Meeting were educational programs sponsored and funded by an outside organization, independently organized, and offered. This symposium was supported by AstraZeneca through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 4/27/2023

Dilon Technologies

Using Real Time Margin Assessment for Successful One-Stage Lumpectomy in Patients with Invasive Carcinoma and DCIS


Description:

Positive lumpectomy margins are associated with an increased risk for ipsilateral tumor recurrence and necessitate additional procedures to achieve acceptable margins. Re-excision rates are higher in patients with ductal carcinoma in situ (DCIS) versus those with invasive carcinoma. The purpose of this program is to lead a discussion on the clinicopathologic characteristics, surgical techniques, and other outcomes associated with re-excision over time following primary breast conserving surgery.

Faculty:

  • Freya R. Schnabel, MD
    Professor, Department of Surgery at NYU Grossman School of Medicine, Director of Breast Surgery NYU Langone

For More Information:

Contact Nancy King at nking@dilon.com.


Note: This webinar is supported by Dilon Technologies through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 4/10/2023

Exact Sciences

24th Annual Meeting Symposium
Current Controversies in the Care of Patients With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer in the Era of Genomics


Program Objectives:

  • Review the wealth of data on the Oncotype DX Breast Recurrence Score® test in pre- and postmenopausal patients
  • Interrogate current controversies at the intersection of genomic testing with patient menopausal status, local regional recurrence, and clinicopathologic features
  • Discuss how guidelines have been informed by TAILORx and RxPONDER trials

Speakers:

  • Tari King, MD, Chief, Breast Surgery, Dana Farber/Brigham and Women's Hospital
  • Christy Russell, MD, Vice President, Medical Affairs, Exact Sciences
  • Jennifer Racz, MD, Director, Medical Affairs, Oncology, Exact Sciences

For More Information:

Go to www.OncotypeIQ.com.


Note: Symposia at the Society's 24th Annual Meeting were educational programs sponsored and funded by an outside organization, independently organized, and offered. This symposium was supported by Exact Sciences through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 4/26/2023

Mammotome

24th Annual Meeting Symposium
Revolutionizing Breast Cancer Surgery


Overview:

See how surgeons around the world are using a single platform to achieve optimal clinical results while tailoring treatments for their patients. Enjoy hands-on experience with devices from biopsy to surgery and see what new technologies are on the horizon.

Faculty:

  • Michael Alvarado, MD, University of California San Francisco
  • Kandace P. McGuire, MD, Virginia Commonwealth University
  • Eirini Pantiora, MD, Uppsala University Hospital, Sweden
  • Rhiana Menen, MD, St. Luke's, Idaho

Agenda:

  • Evidence-Based Decisions: What Will You Decide?
  • Changing the Standard: The Evolution of Magtrace®
  • Clinical Roundup: Thinking Global
  • Ready, Set, Action! The Future of Magnetic Localization

For More Information:

Go to www.mammotome.com.


Note: Symposia at the Society's 24th Annual Meeting were educational programs sponsored and funded by an outside organization, independently organized, and offered. This symposium was supported by Mammotome through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 4/28/2023

Merit Oncology

24th Annual Meeting Symposium
Disruptive Innovation: Harness the Power of Radar


Overview

SCOUT® Radar localization exclusively spans the care continuum from time of biopsy placement to targeted axillary dissection to excellent surgical outcomes. Discover the state-of-the art localization techniques practiced by key opinion leaders from around the country. Learn how recent product innovations enable placing SCOUT under MRI guidance, future platform enhancements and the clinical and economic rationale for placing SCOUT at Time of Biopsy, providing a better patient experience, and streamlining workflow.


Note: Symposia at the Society's 24th Annual Meeting were educational programs sponsored and funded by an outside organization, independently organized, and offered. This symposium was supported by Merit Oncology through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 4/28/2023

Myriad Genetics

Mastering Breast Cancer Genetics and Genomics Series: Part 1 — Foundations and Application of Germline Testing


Overview

Welcome to the first installment of a 3-part series centered around the entire genetics and genomics landscape in breast cancer, covering patients at high risk, those who are newly diagnosed, undergoing treatment, or in survivorship. This series will equip you with the expertise to seamlessly integrate genetic and genomic testing into your clinical practice.

In part 1, we will delve into the foundations and applications of germline testing. Join us as we engage with experts in the field, including Jennifer Lazzara, DNP, ARNP, CGRA, who leads a Breast Cancer Genetics Clinic at Cancer Care Northwest, and Laura Brzeskiewicz, CGC, and Medical Science Liaison Manager at Myriad Genetics.


Note: This webinar is supported by Myriad Genetics through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 11/30/2023

Natera

Detect. Monitor. Optimize: Signatera's Impact on Breast Cancer Management


Overview:

Watch this informative webinar where subject matter experts in breast cancer review the various clinical applications of MRD testing using ctDNA testing to monitor high-risk patients. Learn more about the latest Signatera™ data in high-risk breast cancer:

Speakers:

  • Dr. Minetta Liu, Chief Medical Officer, Natera Oncology
  • Dr. Barry Rosen, Breast Surgical Oncologist, Advocate Good Shepard Hospital
  • Dr. Angel Rodriguez, Breast Medical Oncologist, Medical Director, Natera Oncology

For More Information:

Please contact abet@natera.com.


Note: This webinar is supported by Natera through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 12/04/2023

Perimeter Medical Imaging AI

24th Annual Meeting Symposium
Act in the Moment: OCT adds real-time clarity on margin status


Overview

View the replay of this educational session at the American Society of Breast Surgeons' 2023 Annual Meeting on how Perimeter’s margin visualization technology gives surgeons the real-time insights they need to personalize clinical decisions at the point of care.


Note: Symposia at the Society's 24th Annual Meeting were educational programs sponsored and funded by an outside organization, independently organized, and offered. This symposium was supported by Perimeter Medical Imaging AI through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 4/28/2023

 2022 Events on Demand

Endomag

ImpediMed

Mammotome

Merit Medical

Natera

PeerView Institute

Perimeter Medical Imaging, AI

Physicians’ Education Resource®, LLC (PER®)

PreludeDx


Endomag

23rd Annual Meeting Symposium
Controversy in breast and axilla surgical guidance: Not all seeds and tracers are created equal


Moderator:

  • Susan Boolbol, MD

Panelists:

  • Brigid Killelea, MD, FACS
  • Michael Alvarado, MD
  • Anne Peled, MD
  • Lucy De La Cruz, MD

Description:

Not all seeds and tracers are created equal… join us as we take a deep-dive in to the technologies currently available for seed localization and axillary staging, alongside a world-class panel of breast surgical oncologists, with years of collective experience across all available seed localization devices on the market. The great localization debates will tackle everything from seed reliability to MRI visibility, metal instruments, accuracy of measurement, clinical efficacy, and much more.

That’s followed by the world-first, in-person launch of the next generation Sentimag® system and new Magseed® markers - built by Endomag, designed by you. Taking on board feedback from thousands of physicians worldwide, see how the new system has built on the strengths that have made Sentimag® so widely adopted, plus added an abundance of new advanced features.


Note: Symposia at the Society's 23rd Annual Meeting were educational programs sponsored and funded by an outside organization, independently organized, and offered. This symposium was supported by Endomag through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 4/06/2022

ImpediMed

PREVENT Meets Primary Endpoint:
A Detailed Look at the Practice-Changing Results and Real-World Experience with Breast Cancer-Related Lymphedema Prevention Cancer Care


Description:

PREVENT, the largest randomized clinical trial to assess lymphedema prevention, met its primary endpoint. Join our panel of experts as they debate the recently published results and implications for the future of breast cancer care. Topics covered will include the importance of early lymphedema detection and intervention, supporting clinical evidence, and real-world experience with clinical implementation. Discover how providing your patients with a lymphedema prevention program provides optimal patient care and can positively impact your practice.

Moderated By:

  • Dr. Pat Whitworth
    Director
    Nashville Breast Center

Faculty:

  • Dr. Beth DuPree
    Breast Surgeon
  • Dr. Manpreet Kohli
    Breast Surgeon
    Breast Program Director Monmouth Medical Center
  • Dr. Chirag Shah
    Co-Director Comprehensive Breast Program
    Director of Breast Cancer Radiation Oncology and Director of Clinical Research, Department of Radiation Oncology, Cleveland Clinic

Educational Objectives:

  • Understand the latest evidence from the PREVENT trial
  • Discover the benefits of identifying and treating lymphedema at the subclinical stage
  • Learn the best practices and economics for implementing a lymphedema prevention program

Note: This webinar is supported by ImpediMed through a marketing grant. It is not part of the official ASBrS online program and no AMA PRA Category 1 Credits™ have been assigned to them by the ASBrS.
Originally Aired: 3/22/2022

Mammotome

23rd Annual Meeting Symposium
De-Escalation of Axilla Surgery with Magnetic Markers


Program Objective:

Go beyond wire-free localization into the advanced procedures of TAD and Delayed SLNB. Top experts from around the world review the latest data, the emerging procedures, and share their OR footage of their experiences. Get a glimpse of what’s on the horizon with the next generation Sentimag and dive into the ongoing research.

Agenda:

  • The Latest Magseed® TAD Data
    Mr. Peter Barry, London’s Royal Marsden
  • Delayed SLNB: The Future of Axillary Staging
    Kandace P. McGuire, MD - VCU
    Melissa Fana, MD - Northwell Health
  • Magtrace Efficacy for SLNB Post-NAC
    Dr. Stefan Paepke, MD - Technical University of Munich
  • SentiNOT 2.0 Trial and Recruitment Process
    Betsy Bonefas, MD – Baylor College of Medicine

Note: Symposia at the Society's 23rd Annual Meeting were educational programs sponsored and funded by an outside organization, independently organized, and offered. This symposium was supported by Mammotome through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 4/08/2022

Merit Medical

23rd Annual Meeting Symposium
Disruptive Innovation: Harness the Power of RADAR


Description:

SCOUT® Radar localization exclusively spans the care continuum from time of biopsy placement to Targeted Axillary Dissection to excellent surgical outcomes. Discover the state-of-the art localization and lymphatic mapping techniques practiced by key opinion leaders from the Cleveland Clinic and University of Colorado. Learn about upcoming SCOUT product enhancements and the clinical and economic rationale for placing SCOUT at Time of Biopsy.

Panelists:

  • Brian Czerniecki, MD, PhD
  • Colleen Murphy, MD, FACS
  • Anne Peled, MD
  • Stephanie Valente, DO, FACS

Note: Symposia at the Society's 23rd Annual Meeting were educational programs sponsored and funded by an outside organization, independently organized, and offered. This symposium was supported by Merit Medical through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 4/08/2022

Natera

Better Together: ctDNA and Germline Testing


Description:

In this 30 minute clinical presentation, hear from Dr. Angel Rodriguez on how germline and somatic testing together can inform your surgical decisions, and identify more patients at high risk of cancer recurrence. This presentation will review the portfolio of Natera oncology solutions for germline and somatic testing including Signatera molecular residual disease (MRD) testing and Empower hereditary cancer testing (HCT).

For More Information:

Contact Wing-Kit Chu, Associate Director, Hereditary Cancer Marketing, at wichu@natera.com.


Note: This webinar is supported by Natera through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 8/03/2022

PeerView Institute

23rd Annual Meeting Symposium
Expanding the Benefits of PARP Inhibitor Therapy to More Patients With Breast Cancer and Earlier Disease Settings: Multidisciplinary Perspectives on How to Maximize the Potential of PARP Inhibitors and Optimize Their Use as Part of Multimodal Management of Breast Cancer


Program Objectives:

Upon completion of this CE activity, participants will be able to:

  1. Describe DNA damage response (DDR) pathways and the rationale for therapeutic targeting of DDR with PARP inhibitors in early and advanced breast cancer
  2. Identify patients with breast cancer who might benefit from treatment with PARP inhibitors based on current evidence and best practices for biomarker testing
  3. Integrate PARP inhibitors into evidence-based, individualized treatment plans for eligible patients with early and advanced breast cancer considering latest efficacy and safety data in the context of clinical practice or clinical trials
  4. Manage treatment-related adverse events in patients receiving PARP inhibitors for breast cancer treatment

Description:

Poly (ADP-ribose) polymerase (PARP) inhibition is now the standard of care for metastatic breast cancer harboring a germline BRCA1 or BRCA2 mutation, and studies continue to investigate PARP inhibitors as monotherapies or in rational combinations. Most recently, exciting results have revealed a potential role for PARP inhibitor therapy in earlier disease settings where there is a possibility for cure, heralding a new era of targeted therapy for patients with breast cancer. In order to maximize the benefits of these advances, it is crucial for the multidisciplinary breast cancer care team to keep current with the latest data and expert recommendations to effectively integrate PARP inhibitor therapy into clinical practice, as well as genetic counseling and biomarker testing to refine individualized therapy selection.

This PeerView Live Clinical Consults event for in-person and virtual attendees will provide essential information on the biologic rationale for targeting PARP, the latest data and their practical implications, guidance for optimizing biomarker testing, and strategies for improving multidisciplinary collaboration so that patients with breast cancer can make the most of the recent advances with PARP inhibitor therapy.

Accreditation, Support, and Credit:

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc.


Note: This satellite symposium is supported by AstraZeneca and Merck & Co., Inc. through independent educational grants. This activity is provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. CME credits for this activity will be provided by Medical Learning Institute, Inc. It is not part of the official program of the ASBrS*. This activity is free to all registered attendees. (*An independent symposium fee from Medical Learning Institute, Inc. was provided to the ASBrS in order to offer this satellite symposium during the 23rd Annual Meeting.)
Originally Aired: 4/08/2022

Perimeter Medical Imaging, AI

Don't Operate in the Dark. The Power to See More With OCT


Description:

Lumpectomy re-excisions remain a challenge for breast surgeons. Hear from Dr. Beth DuPree, an early OCT user, and Dr. Michele Carpenter, who described OCT as “like having a pathology slide in the OR.”

Speakers:

  • Michele Carpenter, MD, FACS
    Breast Surgeon
    Orange, CA
  • Beth DuPree, MD, FACS, ABOIM
    Breast Surgeon
    Sedona, AZ

For More Information:

Contact Linda Thomas, lthomas@perimetermed.com, 972‑672‑9700.


Note: This webinar is supported by Perimeter Medical Imaging, AI, through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 12/06/2022

Perimeter Medical Imaging, AI

23rd Annual Meeting Symposium
OCT + Future AI: Changing the Paradigm for Intraoperative Margin Visualization


Featured Guests:

  • Moderator: Dr. Richard Fine, Margaret West Comprehensive Breast Center, Memphis, TN
  • Dr. Amelia Tower, Texas Health Breast Specialists, Fort Worth, TX
  • Dr. Maryam Elmi, The START Center for Cancer Care, San Antonio, TX

Join us for an educational session on the intraoperative use of Perimeter’s groundbreaking margin visualization technology powered by Optical Coherence Tomography (OCT), bringing clarity to margin status at the point of care.

This presentation will cover:

  • Technology behind Perimeter’s S-Series OCT, delivering high-resolution specimen imaging for intraoperative margin visualization
  • OCT correlations with pathology
  • Workflow for bringing OCT into your OR
  • Lumpectomy case reviews, including recognizing suspicious tissues
  • Bringing AI* to the operating room and investigational study updates
  • Panel discussion and Q&A

*Perimeter is currently conducting a randomized control trial to assess its B-Series OCT imaging platform combined with AI technology on the impact of positive margin rates during breast conservation surgery. Perimeter B-Series OCT with ImgAssist AI is not available for sale in the United States. CAUTION: Investigational Device. Limited by U.S. law to investigational use.

Perimeter’s S-Series OCT is cleared by the FDA and available for sale in the U.S.


Note: Symposia at the Society's 23rd Annual Meeting were educational programs sponsored and funded by an outside organization, independently organized, and offered. This symposium was supported by Perimeter Medical Imaging, AI, through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 4/08/2022

Physicians’ Education Resource®, LLC (PER®)

23rd Annual Meeting Symposium
Navigating Adjuvant Decision-Making for High-Risk Early-Stage Hormone Receptor-Positive Breast Cancer: An Expert Tumor Board Discussion


Overview:

During this live satellite symposium, a multidisciplinary panel of experts in the management of early-stage HR+/HER2- breast cancer will engage in a case-based discussion regarding the personalization of adjuvant therapy for these patients, particularly those with high-risk disease. Topics will include clinical and molecular factors for risk assessment, recent clinical data with endocrine regimens integrating CDK4/6 inhibitors, and management of adverse events associated with new agents. This program will highlight current best practices and the integration of emerging data into daily practice to optimize outcomes for patients with early-stage HR+/HER2- breast cancer, using a lively tumor-board format with opportunity for audience questions and interaction.

For help or questions please contact: info@gotoper.com.


Note: Symposia at the Society's 23rd Annual Meeting were educational programs sponsored and funded by an outside organization, independently organized, and offered. This symposium was supported by Physicians’ Education Resource®, LLC (PER®) through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 4/09/2022

PreludeDx

Newly Published Data Review of DCISionRT Randomized SweDCIS Results and the Clinical Utility for Oncoplastic Surgical Planning


Description:

Join us for a published data review of the highly anticipated DCISionRT validation results in the randomized SweDCIS patient cohort. Practicing physicians will be discussing implications of this new data and the clinical utility of DCISionRT in minimizing over- and under-treatment of DCIS patients. There will be interactive discussions about meaningful application of DCISionRT into surgical practice and real-world patient case studies regarding oncoplastic surgical planning.

Faculty:

  • Anne Peled, MD
    Co-Director, Sutter CPMC Breast Cancer Program
  • Karen Barbosa, DO, FACOS
    Breast Surgeon and Oncoplastic Surgeon and Medical Director, TidalHealth Delaware Breast Cancer Program
  • Pat Whitworth, MD, FACS
    Breast Surgical Oncology Specialist, Director of the Nashville Breast Center
  • Chirag Shah, MD
    Co-Director of the Comprehensive Breast Program, Cleveland Clinic
  • Troy Bremer, PhD
    Founder and CSO of PreludeDx

For More Information:

Contact alindsay@preludedx.com, cdunn@preludedx.com


Note: This webinar is supported by PreludeDx through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.
Originally Aired: 3/15/2022